The global market for Patient Blood Management was estimated at US$15.2 Billion in 2023 and is projected to reach US$23.6 Billion by 2030, growing at a CAGR of 6.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
By minimizing unnecessary transfusions, PBM also plays a significant role in conserving blood supplies, which are often in limited availability. This approach is vital for healthcare systems, particularly in times of blood shortages or in regions with limited access to blood products. With the rising demand for blood due to aging populations and increasing surgical procedures, PBM ensures that blood is available for patients who need it most while encouraging efficient blood use. This practice not only conserves resources but also lowers healthcare costs associated with blood transfusions, making PBM essential for sustainable healthcare management.
Moreover, PBM promotes better overall outcomes by taking a preventive, individualized approach to managing each patient`s blood needs. Through interventions like iron supplementation, erythropoiesis-stimulating agents, and advanced surgical techniques, PBM prepares patients adequately before surgery or treatment. This comprehensive approach reduces the likelihood of complications, shortens hospital stays, and enhances recovery times. As healthcare increasingly emphasizes patient-centered care, PBM provides a tailored, preventive strategy that aligns with modern principles of healthcare delivery, improving both patient satisfaction and health outcomes.
Another major advancement in PBM is the use of cell salvage and blood-sparing surgical techniques, which minimize blood loss and reduce transfusion needs during surgery. Intraoperative cell salvage devices collect and process a patient's blood during surgery, allowing it to be reinfused back into the patient, thus reducing dependency on donor blood. Additionally, minimally invasive and laparoscopic surgical techniques are becoming increasingly common, as they involve smaller incisions, leading to less blood loss. These techniques are particularly beneficial in high-blood-loss surgeries, such as orthopedic and cardiac procedures. By incorporating cell salvage and minimally invasive techniques, PBM reduces the need for external blood, improving surgical outcomes and supporting resource efficiency.
Pharmaceutical innovations, such as erythropoiesis-stimulating agents (ESAs) and iron supplements, are also playing a critical role in PBM by boosting red blood cell production and addressing anemia without the need for transfusions. ESAs stimulate the bone marrow to produce more red blood cells, which is especially beneficial for patients with chronic anemia or those undergoing chemotherapy. Iron supplements, whether oral or intravenous, support hemoglobin optimization, preparing patients for procedures that may involve blood loss. With these pharmaceutical interventions, PBM offers non-transfusion options for managing anemia, aligning with its goal to enhance patient health while minimizing transfusion requirements. These therapies empower clinicians to tailor PBM strategies to each patient's needs, providing a more effective and less invasive approach to blood management.
For healthcare providers, PBM supports efficient and sustainable resource management by reducing reliance on donor blood, which is often in limited supply. With blood donation rates unable to keep pace with increasing demand, PBM helps preserve blood resources for patients with critical needs, such as trauma or severe bleeding cases. By reducing blood usage through optimized care and non-transfusion interventions, healthcare providers can manage resources more effectively, lowering the risk of blood shortages and ensuring that blood products are available when truly necessary. PBM also decreases costs associated with blood transfusions, including storage, screening, and administration expenses. This cost-efficiency is especially valuable in large hospitals and health systems, where managing blood resources effectively can lead to substantial financial savings.
Enhanced patient outcomes and quality of care are additional benefits of PBM, as it fosters a more patient-centered, individualized approach to healthcare. Through early anemia detection, blood-sparing surgical practices, and non-transfusion options, PBM enables healthcare providers to create personalized care plans tailored to each patient's needs. This customized approach reduces the likelihood of complications and supports faster recoveries, improving patient satisfaction and overall quality of care. By proactively managing patients' blood health, PBM minimizes hospital stays and readmissions, leading to a more streamlined healthcare experience. Together, these benefits improve both the clinical and operational aspects of healthcare delivery, supporting the goal of high-quality, cost-effective, and patient-centered care.
Increasing numbers of surgeries and the rising prevalence of chronic diseases, such as cancer, kidney disease, and cardiovascular conditions, are also fueling the demand for PBM solutions. With these conditions often requiring surgical interventions or frequent hospitalizations, healthcare providers need effective blood management strategies to support patient care while reducing transfusion dependency. PBM protocols are particularly valuable in high-blood-loss surgeries, as they optimize patient blood health before and during procedures, decreasing the need for transfusions. As the volume of surgeries and hospitalizations continues to grow, so does the demand for effective PBM solutions to manage blood efficiently and improve patient outcomes.
Advancements in diagnostic and therapeutic technologies are significantly contributing to PBM market growth, as they enable more precise, effective, and personalized blood management strategies. New diagnostic tools, such as point-of-care testing and advanced anemia screening, allow for early intervention and accurate management of patient blood levels. Surgical innovations, including cell salvage devices and minimally invasive techniques, reduce blood loss during procedures, minimizing the need for donor blood. Pharmaceutical advancements, such as erythropoiesis-stimulating agents and intravenous iron supplements, provide non-transfusion treatment options for patients with anemia. These technological innovations make PBM programs more accessible and effective, supporting their adoption in hospitals and healthcare facilities worldwide.
Supportive regulatory policies and guidelines are also driving growth in the PBM market, as healthcare organizations and governments recognize the value of PBM in improving patient safety and optimizing blood resources. Regulatory bodies like the World Health Organization (WHO) and health ministries in several countries are encouraging healthcare providers to adopt PBM practices as part of their standard care protocols.
Many healthcare systems now require hospitals to implement PBM strategies to comply with quality standards, reduce healthcare costs, and conserve blood resources. Additionally, patient advocacy groups and health organizations have increased educational efforts to promote awareness of PBM benefits among healthcare professionals and the public. These regulatory and advocacy efforts are expanding the adoption of PBM, driving significant growth in the market as providers align with best practices and compliance standards.
Together, these factors - awareness of transfusion risks, increasing surgical and chronic disease prevalence, technological advancements, and supportive regulatory frameworks - are driving robust growth in the Patient Blood Management market. As healthcare systems aim to provide safer, more cost-effective, and resource-efficient care, PBM is becoming a cornerstone of modern, patient-centered healthcare delivery.
Global Patient Blood Management Market - Key Trends & Drivers Summarized
Why Is Patient Blood Management Essential in Modern Healthcare?
Patient Blood Management (PBM) has become a crucial component in modern healthcare, providing a systematic approach to optimize the care of patients who might need blood transfusions. PBM focuses on minimizing the need for blood transfusions by managing anemia, reducing blood loss during surgery, and optimizing patients` red blood cell mass, thereby improving clinical outcomes. The importance of PBM lies in its ability to enhance patient safety by reducing the risks associated with transfusions, such as infections, immune reactions, and transfusion-related complications. This evidence-based approach is especially important for patients undergoing surgeries, trauma cases, or those with chronic anemia, as it reduces dependency on blood products and leads to faster recovery.By minimizing unnecessary transfusions, PBM also plays a significant role in conserving blood supplies, which are often in limited availability. This approach is vital for healthcare systems, particularly in times of blood shortages or in regions with limited access to blood products. With the rising demand for blood due to aging populations and increasing surgical procedures, PBM ensures that blood is available for patients who need it most while encouraging efficient blood use. This practice not only conserves resources but also lowers healthcare costs associated with blood transfusions, making PBM essential for sustainable healthcare management.
Moreover, PBM promotes better overall outcomes by taking a preventive, individualized approach to managing each patient`s blood needs. Through interventions like iron supplementation, erythropoiesis-stimulating agents, and advanced surgical techniques, PBM prepares patients adequately before surgery or treatment. This comprehensive approach reduces the likelihood of complications, shortens hospital stays, and enhances recovery times. As healthcare increasingly emphasizes patient-centered care, PBM provides a tailored, preventive strategy that aligns with modern principles of healthcare delivery, improving both patient satisfaction and health outcomes.
How Are Technological Advancements Enhancing Patient Blood Management?
Technological advancements are significantly enhancing Patient Blood Management by introducing new tools and methods that optimize blood use, minimize blood loss, and improve patient outcomes. One key innovation in PBM is the development of advanced diagnostic tools that allow for early detection and management of anemia before surgery or treatment. Technologies like point-of-care (POC) testing and automated blood analyzers enable rapid hemoglobin assessments and iron deficiency evaluations, allowing healthcare providers to diagnose and treat anemia early. With accurate, real-time diagnostics, clinicians can implement personalized strategies to optimize hemoglobin levels in advance, reducing the likelihood of needing transfusions. These technologies support proactive anemia management, a core component of PBM, ensuring that patients are in the best possible condition before undergoing procedures.Another major advancement in PBM is the use of cell salvage and blood-sparing surgical techniques, which minimize blood loss and reduce transfusion needs during surgery. Intraoperative cell salvage devices collect and process a patient's blood during surgery, allowing it to be reinfused back into the patient, thus reducing dependency on donor blood. Additionally, minimally invasive and laparoscopic surgical techniques are becoming increasingly common, as they involve smaller incisions, leading to less blood loss. These techniques are particularly beneficial in high-blood-loss surgeries, such as orthopedic and cardiac procedures. By incorporating cell salvage and minimally invasive techniques, PBM reduces the need for external blood, improving surgical outcomes and supporting resource efficiency.
Pharmaceutical innovations, such as erythropoiesis-stimulating agents (ESAs) and iron supplements, are also playing a critical role in PBM by boosting red blood cell production and addressing anemia without the need for transfusions. ESAs stimulate the bone marrow to produce more red blood cells, which is especially beneficial for patients with chronic anemia or those undergoing chemotherapy. Iron supplements, whether oral or intravenous, support hemoglobin optimization, preparing patients for procedures that may involve blood loss. With these pharmaceutical interventions, PBM offers non-transfusion options for managing anemia, aligning with its goal to enhance patient health while minimizing transfusion requirements. These therapies empower clinicians to tailor PBM strategies to each patient's needs, providing a more effective and less invasive approach to blood management.
What Are the Benefits of Patient Blood Management for Patients and Healthcare Providers?
Patient Blood Management provides significant benefits for both patients and healthcare providers, improving patient outcomes, reducing healthcare costs, and optimizing the use of limited blood supplies. For patients, PBM enhances safety by minimizing the risks associated with blood transfusions, such as infections, transfusion reactions, and immunologic complications. By employing non-transfusion interventions like anemia management, surgical blood-sparing techniques, and the use of patient's own blood, PBM reduces the potential for adverse reactions and promotes a safer healthcare experience. For patients undergoing major surgeries, PBM offers the assurance of a carefully managed blood strategy that prioritizes their health, reduces the need for transfusions, and leads to quicker recovery times and shorter hospital stays.For healthcare providers, PBM supports efficient and sustainable resource management by reducing reliance on donor blood, which is often in limited supply. With blood donation rates unable to keep pace with increasing demand, PBM helps preserve blood resources for patients with critical needs, such as trauma or severe bleeding cases. By reducing blood usage through optimized care and non-transfusion interventions, healthcare providers can manage resources more effectively, lowering the risk of blood shortages and ensuring that blood products are available when truly necessary. PBM also decreases costs associated with blood transfusions, including storage, screening, and administration expenses. This cost-efficiency is especially valuable in large hospitals and health systems, where managing blood resources effectively can lead to substantial financial savings.
Enhanced patient outcomes and quality of care are additional benefits of PBM, as it fosters a more patient-centered, individualized approach to healthcare. Through early anemia detection, blood-sparing surgical practices, and non-transfusion options, PBM enables healthcare providers to create personalized care plans tailored to each patient's needs. This customized approach reduces the likelihood of complications and supports faster recoveries, improving patient satisfaction and overall quality of care. By proactively managing patients' blood health, PBM minimizes hospital stays and readmissions, leading to a more streamlined healthcare experience. Together, these benefits improve both the clinical and operational aspects of healthcare delivery, supporting the goal of high-quality, cost-effective, and patient-centered care.
What Is Fueling the Growth in the Patient Blood Management Market?
The growth in the Patient Blood Management market is driven by the rising awareness of transfusion-related risks, increasing surgical and chronic disease cases, advancements in diagnostic and therapeutic technologies, and supportive regulatory policies promoting PBM adoption. As awareness grows around the risks and complications associated with blood transfusions, healthcare providers are increasingly seeking safer and more effective alternatives to traditional transfusion practices. Concerns over infections, immunologic reactions, and potential complications have highlighted the need for PBM programs that minimize transfusions and provide safer care options. This shift in clinical perspective has encouraged more hospitals and healthcare facilities to adopt PBM protocols, driving demand for technologies and practices that support comprehensive blood management.Increasing numbers of surgeries and the rising prevalence of chronic diseases, such as cancer, kidney disease, and cardiovascular conditions, are also fueling the demand for PBM solutions. With these conditions often requiring surgical interventions or frequent hospitalizations, healthcare providers need effective blood management strategies to support patient care while reducing transfusion dependency. PBM protocols are particularly valuable in high-blood-loss surgeries, as they optimize patient blood health before and during procedures, decreasing the need for transfusions. As the volume of surgeries and hospitalizations continues to grow, so does the demand for effective PBM solutions to manage blood efficiently and improve patient outcomes.
Advancements in diagnostic and therapeutic technologies are significantly contributing to PBM market growth, as they enable more precise, effective, and personalized blood management strategies. New diagnostic tools, such as point-of-care testing and advanced anemia screening, allow for early intervention and accurate management of patient blood levels. Surgical innovations, including cell salvage devices and minimally invasive techniques, reduce blood loss during procedures, minimizing the need for donor blood. Pharmaceutical advancements, such as erythropoiesis-stimulating agents and intravenous iron supplements, provide non-transfusion treatment options for patients with anemia. These technological innovations make PBM programs more accessible and effective, supporting their adoption in hospitals and healthcare facilities worldwide.
Supportive regulatory policies and guidelines are also driving growth in the PBM market, as healthcare organizations and governments recognize the value of PBM in improving patient safety and optimizing blood resources. Regulatory bodies like the World Health Organization (WHO) and health ministries in several countries are encouraging healthcare providers to adopt PBM practices as part of their standard care protocols.
Many healthcare systems now require hospitals to implement PBM strategies to comply with quality standards, reduce healthcare costs, and conserve blood resources. Additionally, patient advocacy groups and health organizations have increased educational efforts to promote awareness of PBM benefits among healthcare professionals and the public. These regulatory and advocacy efforts are expanding the adoption of PBM, driving significant growth in the market as providers align with best practices and compliance standards.
Together, these factors - awareness of transfusion risks, increasing surgical and chronic disease prevalence, technological advancements, and supportive regulatory frameworks - are driving robust growth in the Patient Blood Management market. As healthcare systems aim to provide safer, more cost-effective, and resource-efficient care, PBM is becoming a cornerstone of modern, patient-centered healthcare delivery.
Scope of the Study
The report analyzes the Patient Blood Management market, presented in terms of market value (US$ Million). The analysis covers the key segments and geographic regions outlined below.Segments
Product (Instruments, Reagents & Kits, Software, Accessories); Component (Whole Blood & Red Blood Cells, Plasma); End-Use (Blood Banks, Hospitals)Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$10.1 Billion by 2030 with a CAGR of a 6.5%. The Reagents & Kits segment is also set to grow at 7.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $4.0 Billion in 2023, and China, forecasted to grow at an impressive 9.8% CAGR to reach $5.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Patient Blood Management Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Patient Blood Management Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Patient Blood Management Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Global Patient Blood Management Market such as Abbott Laboratories, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Biomérieux SA, Bio-Rad Laboratories, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Global Patient Blood Management Market report include:
- Abbott Laboratories
- Asahi Kasei Medical Co. Ltd.
- B. Braun Melsungen AG
- Biomérieux SA
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche LTD.
- Fresenius Se & Co. KGaA
- Grifols, S.A.
- Haemonetics Corporation
- Immucor, Inc.
- Kaneka Corporation
- Livanova PLC
- Macopharma
- Terumo Corporation
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned
- Abbott Laboratories
- Asahi Kasei Medical Co. Ltd.
- B. Braun Melsungen AG
- Biomérieux SA
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche LTD.
- Fresenius Se & Co. KGaA
- Grifols, S.A.
- Haemonetics Corporation
- Immucor, Inc.
- Kaneka Corporation
- Livanova PLC
- Macopharma
- Terumo Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | December 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 15.2 Billion |
Forecasted Market Value ( USD | $ 23.6 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |